Mixed response to tocilizumab for ankylosing spondylitis

  title={Mixed response to tocilizumab for ankylosing spondylitis},
  author={J. Henes and M. Horger and I. Guenaydin and L. Kanz and I. Koetter},
  journal={Annals of the Rheumatic Diseases},
  pages={2217 - 2218}
Since the introduction of tumour necrosis factor (TNF) antagonists for the treatment of ankylosing spondylitis (AS) the majority of patients can be successfully treated. However, individual patients have persistent disease activity. We report on a 36-year-old male patient with HLA-B27-positive AS. No peripheral arthritis or extra-articular manifestation was documented. After insufficient response to standard treatment with non-steroidal anti-inflammatory drugs (NSAIDs), sulfasalazine… Expand
Emerging drugs for axial spondyloarthritis including ankylosing spondylitis
Only non-steroidal anti-inflammatories (NSAIDs) and TNF inhibitors (TNFi) are effective in ankylosing spondylitis (AS), but not all patients successfully respond to these drugs and a subset may have contraindications to their use. Expand
Tailored Treatment of Ankylosing Spondylitis
The pharmacological and nonpharmacological management of As is described, based on recent international recommendations for the management of AS by the Assessment of Spondyloarthritis (ASAS) group, and the evidence regarding the potential role for new drugs is reviewed. Expand
Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
Although some trends for efficacy were seen, there is at present insufficient evidence to support a recommendation for any of these compounds, and none of these new drugs has been shown to reach response rates compared to TNF-blockers. Expand
Lack of efficacy of tocilizumab in severe axial refractory spondyloarthritis: a report of 5 patients.
The present study did not show clear evident short-term symptomatic efficacy of tocilizumab in 5 patients with severe refractory axial SpA, and importantly, the recruited patients were not representative since suffering from a long-lasting, particularlyRefractory and severe disease. Expand
New treatment targets in ankylosing spondylitis and other spondyloarthritides
IL-6, IL-17, Il-12/23 and, to a latter extend, B-cells are the most promising new targets in the treatment of ankylosing spondylitis and other SpAs. Expand
Ankylosing Spondylitis Refractory to Tumor Necrosis Factor Blockade Responds to Tocilizumab
A case of severe AS that was successfully treated with tocilizumab, the interleukin 6 (IL-6) receptor antagonist, after failing all 3 available anti-TNF-α inhibitors is described. Expand
Interleukin 6 Blockade in Spondyloarthritis
To the Editor: The authors read with interest the case report by Cohen, et al on sustained clinical improvement under tocilizumab in a patient with HLA-B27-positive ankylosing spondylitis (AS)1, and add their experience. Expand
Biologic Therapies for Spondyloarthritis: What Is New?
More studies are needed to further examine the lack of effect of anti-TNF treatment on radiographic progression in the axial skeleton, and whether the effect of an early intervention with biologics will prevent the development of bone growth in patients with nonradiographic axial SpA. Expand
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
The ALIGN study shows that IL-6Rα blockade with sarilumab was not an effective treatment for ankylosing spondylitis and was generally well tolerated with a manageable safety profile. Expand
A review on ankylosing spondylitis
Ankylosing spondylitis (AS) is a long-term inflammation of the joints of the spine which is complex, potentially debilitating disease that is insidious in onset, progressing to radiologicalExpand


Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed. Expand
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
Although further validation using data from new trials is still needed, it is concluded that a clinically valid, easy-to-use measure of short-term improvement in AS has been developed. Expand
Imaging and scoring in ankylosing spondylitis.
Because of the efficacy of the novel biologic agents directed against TNFalpha such as infliximab and etanercept in SpA there is a need for spinal imaging techniques that are more sensitive than conventional x-rays. Expand
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
The ASDAS is a validated, highly discriminatory instrument for assessing disease activity in AS, including patient-reported outcomes and CRP levels, and outperformed the BASDAI and its single components in all settings. Expand
The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B
1 Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004;3:69–75. 2 Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14: 548–52. 3 Hibi S,Expand
Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases
The immunohistological findings of a limited sample suggest a role for BM in sacroiliitis, for TNFα and IL6 in early, active lesions, and for TGFβ1 at the time of secondary cartilage and bone proliferation. Expand
TCZ is a promising agent for the treatment of AS and inadequate response to TNF antagonists